HomeCompareLZAGY vs KMB

LZAGY vs KMB: Dividend Comparison 2026

LZAGY yields 0.76% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KMB wins by $16.2K in total portfolio value
10 years
LZAGY
LZAGY
● Live price
0.76%
Share price
$63.41
Annual div
$0.48
5Y div CAGR
39.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.7K
Annual income
$2,840.75
Full LZAGY calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — LZAGY vs KMB

📍 KMB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLZAGYKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LZAGY + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LZAGY pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LZAGY
Annual income on $10K today (after 15% tax)
$64.35/yr
After 10yr DRIP, annual income (after tax)
$2,414.64/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, KMB beats the other by $2,014.99/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LZAGY + KMB for your $10,000?

LZAGY: 50%KMB: 50%
100% KMB50/50100% LZAGY
Portfolio after 10yr
$37.8K
Annual income
$4,026.03/yr
Blended yield
10.66%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

LZAGY
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
4.2
Piotroski
7/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LZAGY buys
2
KMB buys
0
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$LZAGY▼ Sell$1,001 - $15,0002023-12-21
Josh Gottheimer🏢 House$LZAGY▼ Sell$1,001 - $15,0002023-12-05
Daniel Goldman🏢 House$LZAGY▼ Sell$15,001 - $50,0002023-07-10
Josh Gottheimer🏢 House$LZAGY▼ Sell$1,001 - $15,0002021-04-13
Peter Meijer🏢 House$LZAGY▼ Sell$15,001 - $50,0002021-02-17
Peter Meijer🏢 House$LZAGY▼ Sell$1,001 - $15,0002021-01-28
Greg Gianforte🏢 House$LZAGY▲ Buy$15,001 - $50,0002020-01-13
Donna Shalala🏢 House$LZAGY▼ Sell$1,001 - $15,0002019-06-24
Greg Gianforte🏢 House$LZAGY▲ Buy$100,001 - $250,0002018-05-14
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLZAGYKMB
Forward yield0.76%5.25%
Annual dividend / share$0.48$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR39.3%17%
Portfolio after 10y$29.7K$45.9K
Annual income after 10y$2,840.75$5,211.33
Total dividends collected$8.7K$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: LZAGY vs KMB ($10,000, DRIP)

YearLZAGY PortfolioLZAGY Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$10,805$105.46$11,314$613.68$509.00KMB
2$11,710$148.35$12,865$759.19$1.2KKMB
3$12,739$209.30$14,709$943.96$2.0KKMB
4$13,927$296.42$16,919$1,180.17$3.0KKMB
5$15,324$421.90$19,588$1,484.33$4.3KKMB
6$17,001$604.34$22,838$1,879.06$5.8KKMB
7$19,064$872.88$26,832$2,395.60$7.8KKMB
8$21,673$1,274.26$31,788$3,077.63$10.1KKMB
9$25,076$1,885.93$38,000$3,986.82$12.9KKMB
10$29,672$2,840.75$45,872$5,211.33$16.2KKMB

LZAGY vs KMB: Complete Analysis 2026

LZAGYStock

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia and New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was founded in 1897 and is headquartered in Basel, Switzerland.

Full LZAGY Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this LZAGY vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LZAGY vs SCHDLZAGY vs JEPILZAGY vs OLZAGY vs KOLZAGY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.